Clinical trials: Autoimmune Disorder
Type 1 Diabetes, Hypoglycemia
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels…
- Trial name
- MUGGLE (NCT05616273)
- Testing
- Mixed Meal Tolerance Test (MMTT), Arginine Stimulation Test (AST), Home Finger Prick Sample
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Exeter
Progressive Multiple Sclerosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab.
- Trial name
- Mintaka (NCT07282574)
- Testing
- RO7268489, Ocrelizumab
- Where
- 114 sites in Australia, Brazil and 10 more
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis
The purpose of this study is to determine the optimal dosage of etanercept in patients treated for idiopathic juvenile arthritis
- Trial name
- Etaplus (NCT02030613)
- Testing
- Blood test
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis
Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients
Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05503524
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Autoimmune Disease
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory…
- Trial name
- NCT06633042
- Testing
- Universal BCMA-CD19 CART
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Rheumatoid Arthritis
Study Evaluating TMI-005 in Active Rheumatoid Arthritis
The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving…
- Trial name
- NCT00095342
- Testing
- TMI-005
- Where
- 8 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetes Mellitus, Type 1, Pediatric ALL
Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study
More than half of type 1 diabetes (DT1) children are under CSII (Continuous Subcutaneous Insulin Infusion). Several studies showed that despite a patients' follow-up mostly by hospital-based paediatricians, there are still some…
- Trial name
- DEEP (NCT04100070)
- Testing
- Monitoring of the patients
- Where
- France
- Volunteers
- 320 people
- Sponsor
- ISIS Diabete Service
Multiple Sclerosis
tDCS for the Management of Multiple Sclerosis Related Fatigue
This is a pragmatic clinical trial that aims to determine the effect of tDCS on symptomatic fatigue in Multiple Sclerosis (MS) patients.
- Trial name
- NCT03838770
- Testing
- Active tDCS
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- NYU Langone Health
Rheumatoid Arthritis
Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis
Rationale: In rheumatoid arthritis, immune cells cause joint inflammation and destruction in response to autoantigens. Immunosuppressive therapies offer relief but fail to induce tolerance to autoantigens.
- Trial name
- TOLERANT (NCT05251870)
- Testing
- autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
- Where
- 3 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- UMC Utrecht
Myasthenia Gravis, MG
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
- Trial name
- NCT07294170
- Testing
- Efgartigimod IV, Empasiprubart IV, Efgartigimod PH20 SC PFS
- Where
- 37 sites in United States, Belgium and 6 more
- Volunteers
- 70 people
- Sponsor
- argenx
Rheumatoid Arthritis
IL-6 as a Biomarker for Personalized Treatment of PR
Several studies have shown the relevance of the IL6 level before treatment or after 6 months, as a predictive biomarker for the persistence of remission.
- Trial name
- REMISIX (NCT04779983)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Systemic Lupus Erythematosus
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the effects of "Walk With Ease", a moderate-intensity exercise program, on pain, stiffness, and fatigue caused by lupus. Participants will receive a copy of the "Walk With Ease" workbook.
- Trial name
- Walk SLE (NCT02631005)
- Testing
- "Walk With Ease"
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of North Carolina, Chapel Hill
Infection, Rheumatoid Arthritis
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
The purpose of this study is to evaluate whether the risk of serious infections in rheumatoid arthritis patients with tocilizumab is higher than in those with tumor necrosis factor inhibitors using the nationwide real-world data.
- Trial name
- NCT04115423
- Testing
- Tocilizumab, Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
- Where
- South Korea
- Volunteers
- 9,508 people
- Sponsor
- Sungkyunkwan University
Rheumatoid Arthritis
Use of Tocilizumab Drug Levels to Optimize Treatment in RA
Tocilizumab concentrations above 1 mg/L are likely to be sufficient for normalizing C-reactive protein (CRP) production in patients with rheumatoid arthritis (RA).
- Trial name
- TODORA (NCT03895879)
- Testing
- Tocilizumab
- Where
- Netherlands
- Volunteers
- 98 people
- Sponsor
- Reade Rheumatology Research Institute
Arthritis, Rheumatoid, Vitamin D Deficiency
Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis
Recent studies have demonstrated that subjects with low blood levels of vitamin D are at a higher risk of developing autoimmune diseases such as Rheumatoid Arthritis (RA).
- Trial name
- NCT00279461
- Where
- United States
- Sponsor
- Indiana University
Bullous Pemphigoid (BP)
Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC)
Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity.
- Trial name
- BP-EPIC (NCT07649486)
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul Training and Research Hospital
Diabetes, Mellitus, Type 1
A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-congruent Decisions About Screening Children for Type 1 Diabetes and Follow-up Decisions.
This study will design and test patient decision aids to help parents and guardians in Canada make decisions about screening their children for type 1 diabetes.
- Trial name
- NCT07317973
- Testing
- Web-based patient decision aid, Standard materials
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Laval University
Type 1 Diabetes Mellitus
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Primary Objective: to assess the relative bioavailability of a single dose of insulin glargine (Lantus) and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug Secondary…
- Trial name
- NCT01146678
- Testing
- Insulin glargine HOE901, Lixisenatide AVE0010
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients
Intervention therapy study of moringa oliefera extract on the degree of activity of rheumatoid arthritis patients. The research subjects were patients with rheumatoid arthritis-intervention with moringa oliefera for 30 days.
- Trial name
- NCT05665985
- Testing
- Moringa Oleifera
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Universitas Sebelas Maret
Multiple Sclerosis (MS)
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial.
- Trial name
- NCT04121468
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.